Huachaoshenkong (Shanghai) Technology Co., Ltd. has recently made an exciting announcement—it has successfully secured RMB 200 million in a Pre-A round of funding. This pivotal round was co-led by two renowned investors, Sequoia China and Yunqi Capital, with the active participation of multiple institutions and the continued backing of existing shareholders. Xunguang Capital played a crucial role as the exclusive financial advisor in this endeavor. The freshly acquired funds will be strategically allocated towards product development, attracting top-tier talent, advancing clinical research, and bolstering AI infrastructure.

Prior to this, Huachaoshenkong had already made significant strides by completing Angel and Angel+ rounds of financing, amassing a cumulative total of nearly RMB 300 million. The company is at the forefront of AI and ultrasound brain-computer interface technology, having developed a sophisticated three-tier closed-loop technology system capable of writing, reading, and decoding brain signals. Furthermore, it has successfully launched three distinct product lines tailored for research, clinical, and technology applications.

Huachaoshenkong's core team brings together a wealth of multidisciplinary R&D and industrial translation experience. Their vision is to establish the company as a benchmark in China's non-invasive AI brain-computer interface sector and ultimately transform it into a Neuro AI enterprise built on a foundation of brain data. With this latest round of funding, the company is poised to intensify its efforts in recruiting core talent. The founder, along with several participating institutions, also shared their valuable insights on the industry's trajectory and the company's promising development path.